Monthly Archives: September 2015

The relative absence of women from significant leadership roles in the biotech industry has rightfully become a front-and-center topic, in part prompted by a wave of coverage on the subject (here, here, here, here). Liftstream’s recent report, titled “Diversifying the

This blog was written by Rosana Kapeller, CSO of Nimbus Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. A few weeks ago, a member of our board sent an email to a group of biotech CSOs suggesting that

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. After many months (or years) of grinding, your science seems to be working, the market is responding to your story,

With the NASDAQ sector indices still up 17% for the year, and IPOs continuing at a robust pace, the biotech investing climate continues to be an exciting one. Amidst these rising stock prices, or at least perceptions, I frequently get

Biotech has been on a tear over the past few years supported by a combination of scientific advances, great IPO and M&A exit environments, and robust capital markets for fundraising. Watching the public indices gives a good indicator of broader